An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. *
Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community
On July 14, Insulet Corporation announced a global partnership with Calm, a leading consumer mental health company, to provide emotional well-being resources for people living with diabetes, their caregivers, and healthcare professionals.
Insulet is known for its insulin pump technology, specifically its Omnipod® brand of products.
The partnership launches Calm’s first-ever integrated content partnership and collection with a MedTech company, introducing bespoke mindfulness content, The Mind in Range Collection. The collection includes short meditations, a breathing exercise, and a new Calm Sleep Story, designed specifically for the diabetes community.
“The unmet needs and daily realities of people living with diabetes shape how we innovate and who we choose to partner with,” said Manoj Raghunandanan, chief growth officer at Insulet. “Living with this condition requires constant decisions, and over time that responsibility can create real stress and anxiety. Global data suggest that nearly 80% of people living with diabetes suffer burnout from the emotional strain and demands of daily management. We hold ourselves to a clear standard: do more for people while asking less of them. Partnering with Calm recognizes the emotional dimension of diabetes and expands the support we provide beyond physical outcomes.”
Available on the Calm app and website beginning today, the collection features a suite of free-to-access mindfulness tools created for the diabetes community, which includes:
- A Sleep Story narrated by Lila Moss, fashion model and Omnipod user living with type 1 diabetes. Lila shares a soothing narrative that helps listeners unwind and feel supported as they drift to sleep
- A series of guided meditations to help manage stress and restore balance during moments of overwhelm
- A breathing exercise designed to calm the mind and body, ideal for quick resets throughout the day
Global research3 from Insulet shows most people with diabetes want more holistic care—yet mental health needs remain overlooked.
- 66% of people with diabetes and 46% of caregivers report poor‑quality sleep driven by diabetes‑related stress and anxiety
- 62% of people with type 1 diabetes and 60% with type 2 diabetes say they want support that includes mental health and mindfulness
- Among those using mindfulness tools, 39% report less stress and 33% less anxiety and fewer sleep problems
Studies show that mindfulness-based stress reduction can meaningfully reduce stress for people with diabetes over time. Through this partnership, Insulet and Calm aim to normalize conversations around well-being and mental health in diabetes care and make mindfulness simple and accessible.
“Mindfulness can play a powerful role in improving quality of life for people living with diabetes,” said Dr. Chris Mosunic, Calm Chief Clinical Officer. “By combining Calm’s expertise in this area with Insulet’s leadership in diabetes technology, we’re delivering tools and support that reduce cognitive burden and relieve emotional stress to improve mental wellness.”
This partnership reinforces Insulet’s position as a brand that prioritizes whole-person care and empowers healthcare professionals with credible, evidence-based resources to support their patients’ emotional well-being. The initiative will roll out globally with bespoke content available on the Calm and Calm Sleep apps and promoted across Omnipod and Calm channels throughout the year.
To learn more and explore the free guided meditations, breathing exercise, and Lila Moss’s new sleep story, visit the Omnipod × Calm page at omnipod.com/calm.
